Flush with cash, Sanofi may look for a deal; Puma eyes $120M in offering;

@FierceBiotech: Another 5 biotechs are queuing up for $278M in IPOs. Is this a bubble after all? More | Follow @FierceBiotech

@JohnCFierce: I'm happy to see the IPO boom, the rise in valuations and all that. But with booms, the bigger they are, the harder they fall. Don't forget. | Follow @JohnCFierce

@DamianFierce: The FDA is giving Sprout's female libido drug another shot in what is becoming a pretty interesting case study. Coverage | Follow @DamianFierce

@EmilyMFierce: The top 10 biomedical research organizations, ranked by NIH funding. Special report | Follow @EmilyMFierce

> Now that it's unlikely Sanofi ($SNY) will stage a huge buyback of shares held by L'Oreal, analysts wonder what the French drugmaker will do with a boatload of cash, figuring the company might make an M&A splash. News

> California's Puma Biotechnology ($PBYI) is looking to raise about $120 million through a public offering. More

> Perhaps unsurprisingly, Ariad Pharmaceuticals' ($ARIA) up-and-down fortunes with Iclusig landed it on top of a list of the most volatile stocks. Article

> Recro Pharma has filed for a $28 million IPO, looking to bankroll its pipeline of pain drugs. Story

Medical Device News

@FierceMedDev: St. Jude Medical's stock spiked again after an analyst upgrade. Story | Follow @FierceMedDev

@MarkHFierce: FierceBiotechResearch's latest--a look at the top 10 U.S. biomedical research institutions. Report | Follow @MarkHFierce

@MichaelGFierce: Sonrgy grabs rights to UCSD-created ultrasound-nanocarrier tech. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: ConvaTec is closing its New Jersey facility and cutting jobs. Story | Follow @EmilyWFierce

> Two major Dx players in Brazil are on the cusp of major changes. Item

> Surgeons have implanted a 3-D-printed pelvis into a U.K. cancer patient. More

> Smiths Medical adds tracheostomy tubes designed for kids to standard product line. News

Pharma News

@FiercePharma: Perrigo sees growth, but its sales are trimmed by a hit to contract manufacturing. Story | Follow @FiercePharma

@TracyStaton: Double dose of Merck is too much for German version's CEO. Article | Follow @TracyStaton

@EricPFierce: The best biomedical research facilities in the US may not surprise you. Then again maybe it will. Report | Follow @EricPFierce

@GalenMoore: Particularly for drugmakers strong in diabetes, the Gulf region is a hotbed of activity. Story | Follow @GalenMoore

> Mallinckrodt expands pain portfolio with Cadence acquisition. Piece

> Double dose of Merck is too much for German version's CEO. Story

> What's Big Pharma's latest hot spot? The Middle East. Article

> Pharma-funded group hired by U.K. health service to advise on strategy. News

Biotech Research News

> The top 10 biomedical research institutions. Special Report

> CalTech drug delivery method halts HIV infection in mice. Article

> Nasal vaccine protects mice from West Nile virus. Story

> U.K. pledges to reduce use of animals for biomedical research. News

> Gates Foundation delivers an $11.8M grant to fuel tuberculosis R&D. Story

> New therapeutic target for multiple sclerosis could help repair damaged brain cells. Article

Pharma Manufacturing News

> FDA says products recalled by compounder are contaminated. News

> Teva, which has been tightening its supply chain, turns in a surprising financial report. Story

> Jazz is investing up to $68M to build its first manufacturing facility. Article

> Wockhardt's earnings crash under the weight of FDA bans. News

> The FDA reports far fewer new drug shortages, but the problem continues to grow. Article

> Novartis is expanding a plant in Singapore. Item

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.